In recent years, gene therapy has transitioned from a promising idea to a reality for patients, with many of the severe safety issues that emerged in early iterations of the technology being overcome.

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved gene therapy for DMD, which delivers a micro-dystrophin gene via an ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

Gene Therapy Market Share 2025 Increase in the prevalence of chronic disorders, rise in government support, and ethical acceptance of gene ...

Gene therapy promises individualised management of disease for each patient. Even if two individuals suffer from the same ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...